MEDIA

The latest news from Rimon.

For media queries, contact press@rimonlaw.com.

Rimon in the News

Latest News

Rimon Advises Unleash Immuno Oncolytics in Licensing Agreement with TransCode Therapeutics

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA for the treatment of high-risk and advanced cancer, announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. (“Unleash”). Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting…

Read more

Our Stories

Media Contact

We welcome media inquiries. Our attorneys are recognized thought leaders who can provide expert comments on a wide range of topics globally. We also welcome conversations about our innovative legal model.

Fiona Carlon
Marketing Director
press@rimonlaw.com